Stem Cells International / 2015 / Article / Fig 1

Research Article

Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy

Figure 1

Comparison of PFS in the patients of ASCT group and non-ASCT group regardless of risk stratification. The median PFS was prolonged 17.3 months in ASCT group (32.4 versus 15.1 months, ).